Article Text

Download PDFPDF
In rheumatoid arthritis, a polymorphism in the HLA-G gene concurs in the clinical response to methotrexate treatment
  1. Olavio R Baricordi1,
  2. Marcello Govoni2,
  3. Roberta Rizzo1,
  4. Francesco Trotta2
  1. 1Department of Experimental and Diagnostic Medicine, Section of Medical Genetics, University of Ferrara, Italy
  2. 2Department of Clinical and Experimental Medicine, Section of Rheumatology, University of Ferrara, Italy
  1. Correspondence to:
    Professor Olavio R Baricordi
    Section of Medical Genetics, University of Ferrara, Via L.Borsari 46 – 441000, Ferrara, Italy; bri{at}

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

We read with interest the editorial “Methotrexate pharmacogenomics” by Kremer, recently published in the Annals of Rheumatic Diseases.1 Several reports have proposed a fundamental role of the folate pathway in the clinical effects of methotrexate (MTX) treatment in rheumatoid arthritis, mainly due to genetic variations in the methylene tetrahydrofolate reductase (MTHFR) gene. The observations by Hughes et al of ethnic differences in the frequencies of single-nucleotide polymorphisms (SNPs) in the MTHFR coding region suggest possible links between other specific genotypes and MTX response.2

We recently identified an association between …

View Full Text